Safer, Better, More Appropriate: Clinical Trial Design for Pediatric Drug Labels-Reference-Cited by-同舟云学术

Safer, Better, More Appropriate: Clinical Trial Design for Pediatric Drug Labels

Published:2006-04 Issue:2 Volume:40 Page:185-195
ISSN:0092-8615
Container-title:Drug Information Journal
language:en
Short-container-title:Drug Information J

Author:

McCune Susan K.,Mathis Lisa L.,Cocchetto David M.,Ball Karen,Rodriguez W.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug Guides,Pharmacology (nursing)

Link

http://link.springer.com/content/pdf/10.1177/009286150604000207.pdf

Reference24 articles.

1. Bodensteiner JB, Roach ES. Sturge-Weber Syndrome. Mt. Freedom, NJ: The Sturge-Weber Foundation; 1999.

2. Chapieski L, Friedman A, Lachar D. Psychological functioning in children and adolescents with Sturge-Weber syndrome. J Child Neurol. 2000;15:660–665.

3. Miller RS, Ball K, Comi AM, Germain-Lee EL. Growth hormone deficiency in children with Sturge-Weber syndrome. Arch Dis Child. Accepted.

4. Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003;290:905–911.

5. Best Pharmaceuticals for Children Act, Pub. L. No. 107–109. 2002. Available at: http://frweb-gate.access.gpo.gov/hcgi-bin/useftp.cgi?IPaddress-162.140.64.21&filename-publ109.pdf&directory-/diskc/wais/data/107_cong_public_laws. Accessed September 16, 2005.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surrogate Endpoints: Application in Pediatric Clinical Trials;Pediatric Drug Development;2013-07-31

2. The EU paediatric regulation:;European Neuropsychopharmacology;2011-08